Brain-derived neurotrophic factor: The link between amyloid-β and memory loss

Future Neurology

Volumn 6, Issue 5, 2011, Pages 627-639

  Fahnestock, Margaret ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; amyloid ; brain derived neurotrophic factor; CREB; exon; mRNA; neurotrophin; oligomers; tau

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA SECRETASE; LENTIVIRUS VECTOR; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DIETARY INTAKE; DISEASE MARKER; DOWN REGULATION; DRUG PENETRATION; DRUG TRANSPORT; ENTORHINAL CORTEX; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; EXON IX; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; LEARNING; LIFESTYLE MODIFICATION; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; VIRAL GENE THERAPY;

EID: 80052323362     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.11.44     Document Type: Review

References (159)

1. Hyman BT. The neuropathological diagnosis of Alzheimer's disease: Clinical-pathological studies. Neurobiol. Aging 18(4 Suppl.), S27-S32 (1997).
2. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia 7, 263-269 (2011).
3. Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging 24, 1023-1027 (2003).
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
5. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL. Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science 225, 1168-1170 (1984).
6. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: A review of ultrastructural studies. Neurobiol. Aging 24, 1029-1046 (2003).
7. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
8. Rogaeva E, Meng Y, Lee JH et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168-177 (2007).
9. Willnow TE, Carlo AS, Rohe M, Schmidt V. SORLA/SORL1, a neuronal sorting receptor implicated in Alzheimer's disease. Rev. Neurosci. 21(4), 315-329 (2010).
10. Selkoe DJ. Amyloid b-protein precursor: New clues to the genesis of Alzheimer's disease. Curr. Opin. Neurobiol. 4(5), 708-716 (1994).
11. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993).
12. Bilbul M, Schipper HM. Risk profiles of Alzheimer disease. Can. J. Neurol. Sci. 38, 580-592 (2011).
13. Fahnestock M, Marchese M, Head E et al. BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2010.03.019 (2010) (Epub ahead of print). nn Demonstrates the beneficial effects on cognition of raising endogenous brain-derived neurotrophic factor (BDNF) levels by simple changes in lifestyle. It is the first such study to use a higher mammal (dog) rather than a rodent model.
14. Mawuenyega KG, Sigurdson W, Ovod V et al. Decreased clearance of CNS b-amyloid in Alzheimer's disease. Science 330, 1774 (2010).
15. Sharman MJ, Morici M, Hone E et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-b42 in APOE knock-in and knock-out mice. J. Alzheimers Dis. 21(2), 403-409 (2010).
16. Sisodia SS, St George-Hyslop PH. g-secretase, Notch, Ab and Alzheimer's disease: Where do the presenilins fit in? Nat. Rev. Neurosci. 3(4), 281-290 (2002).
17. Glabe C. Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J. Mol. Neursoci. 17, 137-145 (2001).
18. Oddo S, Caccamo A, Tran L et al. Temporal profile of amyloid-b (Ab) oligomerization in an in vivo model of Alzheimer disease. A link between Ab and tau pathology. J. Biol. Chem. 281, 1599-1604 (2006).
19. Yankner BA. The pathogenesis of Alzheimer's disease. Is amyloid b-protein the beginning or the end? Ann. NY Acad. Sci. 924, 26-28 (2000).
20. Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59, 332-345 (2007).
21. Lacor PN, Buniel MC, Furlow PW et al. Ab oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27(4), 796-807 (2007).
22. Walsh DM, Selkoe DJ. Ab oligomers - a decade of discovery. J. Neurochem. 101, 1172-1184 (2007).
23. Lambert MP, Barlow AK, Chromy BA et al. Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448-6453 (1998).
24. Walsh DM, Klyubin I, Fadeeva JV et al. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880), 535-539 (2002).
25. Neve RL, Robakis NK. Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends Neurosci. 21, 15-19 (1998).
26. Ittner LM, Götz J. Amyloid-b and tau - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12(2), 65-72 (2011).
27. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet. 19(R1), R12-R20 (2010).
28. Klein WL. Ab toxicity in Alzheimer's disease: Globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345-352 (2002).
29. LeVine H 3rd. Alzheimer's b-peptide oligomer formation at physiologic concentrations. Anal. Biochem. 335, 81-90 (2004).
30. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003).
31. Gong Y, Chang L, Viola KL et al. Alzheimer's disease-affected brain: Presence of oligomeric A b ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA 100, 10417-10422 (2003).
32. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid b-protein on hippocampal synaptic plasticity: A potent role for trimers. J. Physiol. 572, 477-492 (2006).
33. Lesne S, Koh MT, Kotilinek L et al. A specific amyloid-b protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
34. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 30, 14946-14954 (2010).
35. Kawahara M, Kuroda Y. Molecular mechanism of neurodegeneration induced by Alzheimer's b-amyloid protein: Channel formation and disruption of calcium homeostasis. Brain Res. Bull. 53(4), 389-397 (2000).
36. Lukiw WJ, Bazan NG. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem. Res. 25(9-10), 1173-1184 (2000).
37. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid b-peptide. Trends Mol. Med. 7(12), 548-554 (2001).
38. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22(6), 799-809 (2001).
39. Perry G, Nunomura A, Cash AD et al. Reactive oxygen: Its sources and significance in Alzheimer disease. J. Neural Transm. Suppl. (62), 69-75 (2002).
40. Caccamo A, Maldonado MA, Majumder S et al. Naturally secreted amyloid-b increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J. Biol. Chem. 286, 8924-8932 (2011).
41. Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: Senile plaques and amyloid-b as protective adaptations to Alzheimer disease. Ann. NY Acad. Sci. 1019, 1-4 (2004).
42. Guillozet al., Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol. 60, 729-736 (2003).
43. Iqbal K, Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: Significance, etiopathogenesis, therapeutics and prevention. J. Cell. Mol. Med. 12(1), 38-55 (2008).
44. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Ab 42 fibrils. Science 293, 1491-1495 (2001).
45. Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001).
46. Terwel D, Muyllaert D, Dewachter I et al. Amyloid activates GSK-3b to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172, 786-798 (2008).
47. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Ab immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43, 321-332 (2004).
48. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging 24, 1063-1070 (2003).
49. Masliah E, Sisk A, Mallory M, Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F b amyloid precursor protein. J. Neuropathol. Exp. Neurol. 60, 357-368 (2001).
50. Pennanen L, Götz J. Different tau epitopes define Ab42-mediated tau insolubility. Biochem. Biophys. Res. Commun. 337(4), 1097-1101 (2005).
51. Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid b-induced deficits in an Alzheimer's disease mouse model. Science 316(5825), 750-754 (2007).
52. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to b-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA 99(9), 6364-6369 (2002).
53. Lindwall G, Cole RD. Phosphorylation affects the ability of tau protein to promote microtubule assembly. J. Biol. Chem. 259(8), 5301-5305 (1984).
54. Hernandez F, Avila J. Tauopathies. Cell. Mol. Life Sci. 64(17), 2219-2233 (2007).
55. Shi J, Qian W, Yin X et al. Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: A mechanism involved in tau pathology of Alzheimer disease. J. Biol. Chem. 286(16), 14639-14648 (2011).
56. Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M. Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 1130(1), 206-216 (2007).
57. Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: Promises, pitfalls and prospects. Expert Opin. Ther. Targets 7(1), 101-114 (2003).
58. Yamamoto-Sasaki M, Ozawa H, Saito T, Rösler M, Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res. 824(2), 300-303 (1999).
59. Tong L, Thornton PL, Balazs R, Cotman CW. b-amyloid1-42 impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J. Biol. Chem. 276(20), 17301-17306 (2001).
60. Garzon DJ, Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 27(10), 2628-2635 (2007). nn Demonstrates that soluble, aggregated amyloid-b, but not the fibrillar form found in plaques, decreases cAMP response element binding protein phosphorylation and specific BDNF transcript levels.
61. España J, Valero J, Miñano-Molina AJ et al. b-amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J. Neurosci. 30(28), 9402-9410 (2010).
62. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 107(52), 22687-22692 (2010).
63. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 9, 2459-2464 (1990).
64. Alderson RF, Alterman AL, Barde Y, Lindsay RM. Brain-derived neurotrophic factor increases survival and differentiated function of rat septal cholinergic neurons in culture. Neuron 5, 297-306 (1990).
65. Ghosh A, Carnahan J, Greenberg ME. Requirement for BDNF in activity-dependent survival of cortical neurons. Science 263, 1618-1623 (1994).
66. Lindholm D, Carroll P, Tzimagiogis G, Thoenen H. Autocrine-paracrine regulation of hippocampal neuron survival by IGF-1 and the neurotrophins BDNF, NT-3, and NT-4. Eur. J. Neurosci. 8, 1452-1460 (1996).
67. Bramham CR, Messaoudi E. BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis. Prog. Neurobiol. 76, 99-125 (2005).
68. Verpelli C, Piccoli G, Zanchi A et al. Synaptic activity controls dendritic spine morphology by modulating eEF2-dependent BDNF synthesis. J. Neurosci. 30(17), 5830-5842 (2010).
69. Causing CG, Gloster A, Aloyz R et al. Synaptic innervation density is regulated by neuron-derived BDNF. Neuron 18, 257-267 (1997).
70. Horch HW, Kruttgen A, Portbury SD, Katz LC. Destabilization of cortical dendrites and spines by BDNF. Neuron 23, 353-364 (1999).
71. Lu B. BDNF and activity-dependent synaptic modulation. Learn. Mem. 10, 86-98 (2003).
72. McAllister A, Katz LC, Lo DC. Neurotrophin regulation of cortical dendritic growth requires activity. Neuron 17, 1057-1064 (1996).
73. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J. Neurosci. 21, 6706-6717 (2001).
74. Scharfman HE. Hyperexcitability in combined entorhinal/hippocampal slices of adult rat after exposure to brain-derived neurotrophic factor. J. Neurophysiol. 78, 1082-1095 (1997).
75. Egan MF, Kojima M, Callicott JH et al. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257-269 (2003).
76. Hariri AR, Goldberg TE, Mattay VS et al. Brain-derived neurotrophic factor Val66Met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 23, 6690-6694 (2003).
77. Fukumoto N, Fujii T, Combarros O et al. Sexually dimorphic effect of the Val66Met polymorphism of BDNF on susceptibility to Alzheimer's disease: New data and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B(1), 235-242 (2010).
78. Voineskos AN, Lerch JP, Felsky D et al. The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch. Gen. Psychiatry 68(2), 198-206 (2011).
79. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 57, 846-851 (2000).
80. Holsinger RMD, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: Decreased levels in Alzheimer's disease. Mol. Brain Res. 76, 347-354 (2000).
81. Michalski B, Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Mol. Brain Res. 111, 148-154 (2003).
82. Narisawa-Saito M, Wakabayashi K, Tsuji S, Takahashi H, Nawa H. Regional specificity of alterations in NGF, BDNF and NT-3 levels in Alzheimer's disease. Neuroreport 7, 2925-2928 (1996).
83. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 93, 1412-1421 (2005). n Demonstrates that BDNF levels are decreased in mild cognitive impairment and early Alzheimer's disease (AD).
84. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7, 695-702 (1991).
85. Ando S, Kobayashi S, Waki H et al. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J. Neurosci. Res. 70, 519-527 (2002).
86. Blurton-Jones M, Kitazawa M, Martinez-Coria H et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl Acad. Sci. USA 106(32), 13594-13599 (2009). nn Demonstrates that the beneficial effects of stem cell implantation on synaptic density and learning and memory deficits in transgenic mouse models of AD are due to secretion of BDNF.
87. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl Acad. Sci. USA 92, 8856-8860 (1995).
88. Nagahara AH, Merrill DA, Coppola G et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15(3), 331-337 (2009). nn Demonstrates the beneficial effects of exogenous BDNF administration on learning and memory deficits in animal models of AD.
89. Patterson SL, Abel T, Deuel TA, Martin KC, Rose JC, Kandel ER. Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 16, 1137-1145 (1996).
90. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: Key roles of growth factor cascades and inflammation. Trends Neurosci. 30(9), 464-472 (2007).
91. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters. Genomics 90(3), 397-406 (2007). nn Seminal paper describing the human BDNF gene.
92. Pattabiraman PP, Tropea D, Chiaruttini C, Tongiorgi E, Cattaneo A, Domenici L. Neuronal activity regulates the developmental expression and subcellular localization of cortical BDNF mRNA isoforms in vivo. Mol. Cell. Neurosci. 28, 556-570 (2005).
93. Timmusk T, Lendahl U, Funakoshi H, Arenas E, Persson H, Metsis M. Identification of brain-derived neurotrophic factor promoter regions mediating tissue-specific, axotomy-, and neuronal activity-induced expression in transgenic mice. J. Cell Biol. 128, 185-199 (1995).
94. Timmusk T, Belluardo N, Persson H, Metsis M. Developmental regulation of brain-derived neurotrophic factor messenger RNAs transcribed from different promoters in the rat brain. Neuroscience 60, 287-291 (1994).
95. Liu QR, Walther D, Drgon T et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134B(1), 93-103 (2005).
96. Wong J, Webster MJ, Cassano H, Weickert CS. Changes in alternative brain-derived neurotrophic factor transcript expression in the developing human prefrontal cortex. Eur. J. Neurosci. 29(7), 1311-1322 (2009).
97. Garzon D, Yu G, Fahnestock M. A new BDNF transcript and decrease in BDNF transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J. Neurochem. 82, 1058-1064 (2002). n Original paper showing specific BDNF transcripts are affected in AD.
98. Peng S, Garzon DJ, Marchese M et al. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J. Neurosci. 29(29), 9321-9329 (2009).
99. Pruunsild P, Sepp M, Orav E, Koppel I, Timmusk T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human BDNF gene. J. Neurosci. 31(9), 3295-3308 (2011).
100. Koppel I, Aid-Pavlidis T, Jaanson K et al. Tissue-specific and neural activity-regulated expression of human BDNF gene in BAC transgenic mice. BMC Neurosci. 10, 68 (2009).
101. Levy YS, Gilgun-Sherki Y, Melamed E, Offen D. Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs 19(2), 97-127 (2005).
102. Pardon MC. Role of neurotrophic factors in behavioral processes: Implications for the treatment of psychiatric and neurodegenerative disorders. Vitam. Horm. 82, 185-200 (2010).
103. Weis J, Saxena S, Evangelopoulos ME, Kruttgen A. Trophic factors in neurodegenerative disorders. IUBMB Life 55(6), 353-357 (2003).
104. Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5(6), 311-322 (2009).
105. Wong J, Hyde TM, Cassano HL, Deep-Soboslay A, Kleinman JE, Weickert CS. Promoter specific alterations of brain-derived neurotrophic factor mRNA in schizophrenia. Neuroscience 169(3), 1071-1084 (2010).
106. Gambazzi L, Gokce O, Seredenina T et al. Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments. J. Pharmacol. Exp. Ther. 335(1), 13-22 (2010).
107. Bustos G, Abarca J, Bustos V et al. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease. J. Neurosci. Res. 87(10), 2308-2318 (2009).
108. Webster MJ, Weickert CS, Herman MM, Kleinman JE. BDNF mRNA expression during postnatal development, maturation and aging of the human prefrontal cortex. Brain Res. Dev. Brain Res. 139(2), 139-150 (2002).
109. Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C. BDNF and trkB mRNA expression in the hippocampus and temporal cortex during the human lifespan. Gene Expr. Patterns 6(8), 941-951 (2006).
110. Hayashi M, Yamashita A, Shimizu K. Somatostatin and brain-derived neurotrophic factor mRNA expression in the primate brain: Decreased levels of mRNAs during aging. Brain Res. 749(2), 283-289 (1997).
111. Francis BM, Kim J, Barakat ME et al. Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging.2010.04.003 (2010) (Epub ahead of print).
112. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 119(4), 252-265 (2009).
113. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging - Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 270-279 (2011).
114. Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 258(2), 124-128 (2008).
115. Leyhe T, Eschweiler GW, Stransky E et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J. Alzheimers Dis. 16(3), 649-656 (2009).
116. Yasutake C, Kuroda K, Yanagawa T, Okamura T, Yoneda H. Serum BDNF, TNF-a and IL-1b levels in dementia patients: Comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 256(7), 402-406 (2006).
117. Laske C, Stransky E, Leyhe T et al. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J. Psychiatr. Res. 41(5), 387-394 (2007).
118. Yu H, Zhang Z, Shi Y et al. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J. Clin. Psychiatry 69(7), 1104-1111 (2008).
119. Laske C, Stransky E, Leyhe T et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm. 113(9), 1217-1224 (2006).
120. Angelucci F, Spalletta G, di Iulio F et al. Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr. Alzheimer Res. 7(1), 15-20 (2010).
121. O'Bryant SE, Hobson VL, Hall JR et al. Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement. Geriatr. Cogn. Disord. 31(1), 31-36 (2011).
122. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 37, 1553-1561 (1998). n First demonstration that BDNF can cross the BBB.
123. Rasmussen P, Brassard P, Adser H et al. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp. Physiol. 94(10), 1062-1069 (2009).
124. Seifert T, Brassard P, Wissenberg M et al. Endurance training enhances BDNF release from the human brain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298(2), R372-R377 (2010).
125. Wang H, Ward N, Boswell M, Katz DM. Secretion of brain-derived neurotrophic factor from brain microvascular endothelial cells. Eur. J. Neurosci. 23, 1665-1670 (2006).
126. Fujimura H, Altar CA, Chen R et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb. Haemost. 87, 728-734 (2002).
127. Skornicka EL, Shi X, Koo PH. Comparative binding of biotinylated neurotrophins to a2-macroglobulin family of proteins: Relationship between cytokine-binding and neuro-modulatory activities of the macroglobulins. J. Neurosci. Res. 67, 346-353 (2002).
128. Li G, Peskind ER, Millard SP et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 4(5), E5424 (2009).
129. Gunstad J, Benitez A, Smith J et al. Serum brain-derived neurotrophic factor is associated with cognitive function in healthy older adults. J. Geriatr. Psychiatry Neurol. 21, 166-170 (2008).
130. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int. J. Neuropsychopharmacol. 13(1), 103-108 (2010).
131. Fahnestock M, Peng S, Marchese M, Delvaux ER, Coleman PD. BDNF mRNA levels are decreased in peripheral blood samples from subjects with Alzheimer's disease. Alzheimers Dementia 4(Suppl. 2), T320 (2008).
132. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci. Lett. 328(3), 261-264 (2002).
133. Conforti P, Ramos C, Apostol BL et al. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: Restoration by the neuroprotective compound CEP-1347. Mol. Cell. Neurosci. 39(1), 1-7 (2008).
134. Nagahara AH, Bernot T, Moseanko R et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp. Neurol. 215, 153-159 (2009).
135. Sobreviela T, Pagcatipunan M, Kroin JS, Mufson EJ. Retrograde transport of brain-derived neurotrophic factor (BDNF) following infusion in neo- and limbic cortex in rat: Relationship to BDNF mRNA expressing neurons. J. Comp. Neurol. 375(3), 417-444 (1996).
136. Altar CA, DiStefano PS. Neurotrophin trafficking by anterograde transport. Trends Neurosci. 21(10), 433-437 (1998).
137. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D. Adult neurotrophic factor-secreting stem cells: A potential novel therapy for neurodegenerative diseases. Isr. Med. Assoc. J. 11(4), 201-204 (2009).
138. Zhang Y, Pardridge WM. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res. 1111(1), 227-229 (2006).
139. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32(6), 1378-1384 (2001).
140. Zhang Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 889(1-2), 49-56 (2001).
141. Boado RJ, Zhang Y, Zhang Y, Pardridge WM. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng. 97(6), 1376-1386 (2007).
142. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann. NY Acad. Sci. 1184, 154-172 (2010).
143. Binder DK, Croll SD, Gall CM, Scharfman HE. BDNF and epilepsy: Too much of a good thing? Trends Neurosci. 24(1), 47-53 (2001).
144. DeMarch Z, Giampá C, Patassini S, Bernardi G, Fusco FR. Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 30(3), 375-387 (2008).
145. Apostol BL, Simmons DA, Zuccato C et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 39(1), 8-20 (2008).
146. Jang SW, Liu X, Yepes M et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl Acad. Sci. USA 107(6), 2687-2692 (2010).
147. Massa SM, Yang T, Xie Y et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Invest. 120(5), 1774-1785 (2010).
148. van Praag H, Kempermann G, Gage FH. Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus. Nat. Neurosci. 2(3), 266-270 (1999).
149. Farmer J, Zhao X, van Praag H, Wodtke K, Gage FH, Christie BR. Effects of voluntary exercise on synaptic plasticity and gene expression in the dentate gyrus of adult male Sprague-Dawley rats in vivo. Neuroscience 124(1), 71-79 (2004).
150. Zajac MS, Pang TY, Wong N et al. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 20(5), 621-636 (2010).
151. Cotman CW, Berchtold NC. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25(6), 295-301 (2002).
152. Berchtold NC, Chinn G, Chou M, Kesslak JP, Cotman CW. Exercise primes a molecular memory for brain-derived neurotrophic factor protein induction in the rat hippocampus. Neuroscience 133(3), 853-861 (2005).
153. Falkenberg T, Mohammed AK, Henriksson B, Persson H, Winblad B, Lindefors N. Increased expression of brain-derived neurotrophic factor mRNA in rat hippocampus is associated with improved spatial memory and enriched environment. Neurosci. Lett. 138(1), 153-156 (1992).
154. Williams BM, Luo Y, Ward C et al. Environmental enrichment: Effects on spatial memory and hippocampal CREB immunoreactivity. Physiol. Behav. 73(4), 649-658 (2001).
155. Williams CM, El Mohsen MA, Vauzour D et al. Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. Free Radic. Biol. Med. 45(3), 295-305 (2008).
156. Smith PJ, Blumenthal JA. Diet and neurocognition: Review of evidence and methodological considerations. Curr. Aging Sci. 3(1), 57-66 (2010).
157. Savica R, Petersen RC. Prevention of dementia. Psychiatr. Clin. North Am. 34(1), 127-145 (2011).
158. Rolland Y, Abellan van Kan G, Vellas B. Physical activity and Alzheimer's disease: From prevention to therapeutic perspectives. J. Am. Med. Dir. Assoc. 9, 390-405 (2008).
159. Knaepen K, Goekint M, Heyman EM, Meeusen R. Neuroplasticity - exercise-induced response of peripheral brain-derived neurotrophic factor: A systematic review of experimental studies in human subjects. Sports Med. 40(9), 765-801 (2010).